Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia - Debruyne, F; Gres, A A; Arustamov, D L (Eur Urol, 2008)